Showing results (281-290 of 311) with videos related to

Sort By:
Pageof 32
Clinical and Translational Gastroenterology|December 15, 2012
Upper and Lower Gastrointestinal Findings in PTEN Mutation-Positive Cowden Syndrome Patients Participating in an Active Surveillance ProgramZohar Levi, Hagit N Baris, Inbal Kedar, et al.
Journal of Clinical Gastroenterology|February 19, 2008
The 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitisHemda Schmilovitz-Weiss, Yaron Niv, Orit Pappo, et al.
Medicina (Kaunas, Lithuania)|March 22, 2020
Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care?Christos Liatsos, Apostolis Papaefthymiou, Nikolaos Kyriakos, et al.
Transplantation|April 30, 2003
Expression of MUC2 and MUC4 proteins and cytokines: early markers of intestinal graft rejectionNir Wasserberg, Shashikumar K Salgar, Dinghua Yang, et al.
Gastrointestinal Endoscopy|March 13, 2017
Risk of advanced lesions at the first follow-up colonoscopy after polypectomy of diminutive versus small adenomatous polyps of low-grade dysplasiaOrly Sneh Arbib, Valentina Zemser, Yaara Leibovici Weissman, et al.
World Journal of Gastroenterology|November 3, 2011
MicroRNAs as a potential prognostic factor in gastric cancerBaruch Brenner, Moshe B Hoshen, Ofer Purim, et al.
World Journal of Gastroenterology|October 31, 2014
Membrane-bound mucins and mucin terminal glycans expression in idiopathic or Helicobacter pylori, NSAID associated peptic ulcersYaron Niv, Doron Boltin, Marisa Halpern, et al.
Gut|February 21, 2024
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updatesMassimo Rugge, Robert M Genta, Peter Malfertheiner, et al.
Gut|April 12, 2012
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus ReportPeter Malfertheiner, Francis Megraud, Colm A O'Morain, et al.
Plos One|March 26, 2013
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's diseaseSatish Keshav, Tomáš Vaňásek, Yaron Niv, et al.
Pageof 32